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Abstract
Background: Upper Respiratory tract infection (URTI) or common cold is very 
prevalent in children particularly in young children. Leukotriene receptor antagonists 
(LTRAs) like montelukast are effective drugs in asthma and some other respiratory 
diseases. Our purpose was to study preventive effects of montelukast on pediatric URTI. 
Methods: This randomized, placebo-controlled, and double blind trial was performed on 
450 healthy children aged 1-5 year in Amir Kabir Hospital, Arak, Iran. Children were 
randomized 1:1 to placebo group or montelukast group for 12 weeks. Number of URTI 
episodes and duration were the primary end points and were compared at baseline and after 
termination of treatment.
Results: Mean age was 28 ± 12.3 months. Mean of URTI episodes was 0.7 ± 0.57 in children 
treated with montelukast and 1.27 ± 0.72 in children treated with placebo, respectively. 
Differences were statistically significant (P =0.01). A significant difference was seen in URTI 
duration between two study groups (6.3 ± 6.1 vs 4.1 ± 3.9, P = 0.05). In addition, duration of 
fever was shorter in children receiving montelukast (P=0.001).
Conclusion: Our study indicates that 3 month treatment with montelukast is effective 
for reducing the incidence of URTI in young children. This treatment has an acceptable 
safety without any serious concern.
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Upper Respiratory tract infection (URTI) or common cold 
is one of the most prevalent problems in children. It has 
usually a higher incidence rate in children younger than 
5 years.1,2 
URTI is usually the main cause of hospital admission 
and missed days at work or kindergarten. Of note, it has 
a high cost to the society. Ear infection, sinusitis, and 
exacerbations of reactive airway diseases are important 
complications of URTI.1-3 Noteworthy, there is no specific 
treatment for pediatric URTI. Many viruses and bacteria 
are involved in the pathogenesis of URTI, therefore it is 
difficult to have a single vaccine which can prevent the 
occurrence of childhood URTI.4 In many cases, URTI is 
self-diagnosed and self-treated and supportive therapies 
can solve the problem. However, in cases with high 
fever and serious infections antibiotics are ordered.4,5
Leukotrienes have a pivotal role in the initiation and 
development of some inflammatory reactions including 
URTI. They are involved in congestion, bronchoconstriction, 
and bronchospasm.6  They can be suppressed through 
two ways; inhibition of lipoxygenase which is involved 
in the production of leukotrienes and blockade of its 
receptor. 
Leukotriene receptor antagonists (LTRAs) like montelukast 
and zafirlukast have well established effects for prevention 
and treatment of asthma in children. In addition, they have 
pediatric application in exercise-induced bronchospasm 
and allergic rhinitis.7,8 
Montelukast is approved in children older than 12 
months. It is generally well tolerated and shows many 
positive effects in asthmatic patients.9,10  Headache and 
mild gastrointestinal upset are frequent side effects of 
montelukast.11 Due to presence of leukotrienes in URTI, it 
is expected that LTRAs can offer therapeutic benefits. Till 
now, limited studies have provided evidence for effects of 
montelukast in URTI and present data are uncertain. We 
aimed at assessing the prophylactic role of montelukast on 
childhood URTI.
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Materials and Methods
Study design
The study was performed in Amir-Kabir Hospital, Arak, 
Iran. Four hundred and fifty healthy children aged 1-5 
years were included. The study was done between August 
2017 and May 2018. Participants were excluded if they 
had acute or chronic air-way disease, active URTI, use of 
bronchodilators, use of corticosteroids and montelukast, 
history of hypersensitivity, seasonal or allergic rhinitis, and 
chronic heart disease. Sealed envelopes with an enclosed 
assignment were used for allocation concealment. Four 
hundred and fifty individuals were calculated with the 
assumption of 15% dropout in number of the subjects 
for detection of differences in URTI duration and URTI 
episode. The power was 80%. This was a randomized, 
placebo-controlled, and single center study. We used simple 
randomization method. All participants and caregivers 
were masked. Subjects were randomized 1:1 to oral 5 mg/
day montelukast or placebo for 12 weeks. They were asked 
to have the drug or placebo in the morning. 
Efficacy measures
Number of URTI episodes and URTI duration were the 
primary end points. Sneezing, coughing, nasal congestion, 
and fever (body temperature > 37.3ºC, axillary) were 
suggestive for URTI if subjects had at least 2 symptoms.12 
URTI duration was measured at diagnosis day until the day 
which all symptoms were resolved. Parents were trained for 
symptoms of URTI and they were asked to record number 
and duration of URTI episodes. Secondary outcomes were 
adverse effects of drugs, use of antibiotics and antipyretics, 
and absence from kindergarten.
Safety measures
Physical examination was done at baseline and every month 
by physician. Subjects were visited monthly for 3 months. 
For assessment of side effects of the drugs, participants 
were monitored weekly by phone for any systemic upset 
and hypersensitivity. Parents were trained for possible 
adverse effects of monteluksat and were asked to call the 
clinic immediately in case of any problem. 
Data analysis
Kolmogorov–Smirnov was used to test normal distribution 
of data. Student t test, Mann–Whitney tests, x2 test, 
and Fisher’s exact were used for data analysis. P<0.05 
was considered as statistical significance. Analysis was 
performed using SPSS software version 21.0.
Results
Of the 450 individuals who were included 70 children did 
not receive the treatments (27 did not use the medications, 
and 21 met the exclusion criteria). Twenty two children 
were lost to follow up and 380 participants had complete 
observation over the course of 3 months. Table 1 shows 
baseline characteristics of subjects. The mean age was 
28 ± 12.3 months with an excess of males (58%). At 
baseline, no significant differences were noted in children’s 
characteristics. Flow diagram for study participants is 
shown in Figure 1. For possible confounding factors, birth 
order (first birth or not), number of family member(less 
than or equal to four), number of rooms in the house, and 
number of sibling (less than or equal to one) were analyzed. 
Confounding factors were equally distributed between the 
two groups (P>0.05). As shown in Table 2, the reported 
mean number of URTI episodes was 0.7 ± 0.57 in children 
treated with montelukast and 1.27 ± 0.72 in children 
treated with placebo. The between group differences were 
statistically significant (P=0.001). URTI duration was 
significantly shorter in montelukast group (4.1 ± 3.9 (day) 
vs 6.3 ± 6.1 (day), P=0.05). Frequency of fever was 63.5 % in 
montelukast group and 86.8 % in placebo group (P=0.001). 
In addition, duration of fever was significantly shorter in 
montelukast group (2.7 ± 2.4 day) compared with placebo 
group (4.84 ± 2.86 day, P=0.001). There were significant 
differences in use of antibiotics and antipyretics between 
two study groups (P<0.05). Frequency of antibiotic use 
was 14 % in montelukast group and 25 % in placebo 
group; the between group difference were statistically 
significant (P=0.007). Moreover, frequency of antipyretics 
use was significantly higher in children who received 
placebo (P=0.001). Rhinitis and cough had higher rate of 
incidence in the placebo group (P=0.05). The incidence 
of otitis, pneumonia, and pharyngitis was similar in both 
groups (P>0.05) and the mean number of outpatient 
Table 1. Baseline characteristics of participants. Data are shown as mean ± SD and number (%).
Characteristics Montelukast group (n=190) Placebo group (n=190) P 
Age, month 29.53 ± 13.29 27.04 ± 11.95 0.05
Male 100 (52.6%) 120 (63.2%) 0.07
Parental smoking 70 (36.7%) 72(37.4%) 0.80
Previous hospitalization 85 (45.3%) 93 (49.5%) 0.67
N of rooms in the house
Less than two 138 (72.6%) 142 (74.7%) 0.62
More than two 52 (27.4%) 48 (25.3%) 0.80
N of family members
Less than four 139 (73.2%) 139 (73.2%) 1.00
More than four 51 (26.8%) 51 (26.8%) 0.90
Birth order
First birth 71 (37.4%) 57 (30%) 0.13
Second birth or above 119 (62.6%) 133 (70%) 0.22
Sibling
One and less than one 137 (72.1%) 139 (73.2%) 0.80
More than one 53 (27.9%) 51 (26.8%) 0.61
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visit was statistically higher in placebo group (P=0.001). 
However, there were no differences in the frequency of 
hospitalization in study groups (P=0.19).
Discussion
This randomized and placebo-controlled trial showed 
that 3 month treatment with montelukast is effective for 
reducing the incidence of URTI in young children. This 
study confirmed that montelukast significantly reduced 
URTI episodes and URTI duration. Upper respiratory 
tract infection (URTI) or common cold is one of the most 
prevalent diseases and is a leading reason for unscheduled 
outpatient visits in adults and in children.1,13 Children 
particularly preschool children may experience URTI up 
to 6-10 times per year.14 Many viruses are associated with 
nasal discharge, cough, nasal congestion, sore throat, 
sneezing, lower respiratory infection, and otitis media. 
URTI has a high cost to society and is usually associated 
with kindergarten absence and missed days at works for 
parents.4 The leukotrienes exhibit a number of biological 
effects such as attraction and activation of leukocytes, 
contraction of bronchial smooth muscles, and stimulation 
of vascular permeability.15 Some studies have shown 
that in infants with respiratory syncytial virus (RSV) 
Figure 1. Consort diagram detailing study subjects.
Table 2. Effects of treatments on study endpoints. Data are shown as mean ± SD and number (%)
Characteristics Montelukast group (n=190) Placebo group (n=190) P 
Number of URTI episode 0.7 ± 0.5 1.2 ± 0.7 0.001
Average duration of URTI (day) 4.1 ± 3.9 6.3 ± 6.1 0.05
Absence from kindergarten 19 (10%) 24 (13.2%) 0.26
Parent missed works 38 (21.1%) 66 (35.3%) 0.001
Frequency of adverse effects 0 0 1.00
Fever 120 (63.5%) 163 (86.8%) 0.001
Cough 112 (59.5%) 146 (77.4%) 0.001
Unscheduled visits 121 (64.2%) 43 (86.8%) 0.001
Number of outpatient visit 0.69 ± 0.54 1.26 ± 0.72 0.001
Incidence of otitis 4 (28.6%) 10 (71.4%) 0.10
Incidence of pneumonia 12 (40%) 18 (60%) 0.25
Incidence of pharyngitis 11 (33.3%) 22 (66.7%) 0.04
Hospitalization 12 (38.7%) 19 (61.3%) 0.19
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bronchiolitis, levels of leukotriene C4 in nasal lavage fluid 
were significantly higher than healthy controls, which 
persisted after one month of acute infection.16  Moreover, 
an increase in leukotriene 4 levels in nasal secretions 
and a relationship between symptoms and leukotriene 
levels have been reported in experimental models of 
infection by influenza A, rhinovirus, and RSV.17,18 Many 
investigations have assessed the role of montelukast in 
respiratory problems such as chronic asthma, seasonal 
allergic rhinitis, mild asthma, and respiratory syncytial 
virus post-bronchiolitis. A work by Yoshihara showed 
that LTRAs like monteluksat can reduce asthma attacks 
in response of common cold in young children.19 A study 
demonstrated that 8 weeks treatment with montelukast 
is able to improve asthmatic status in children with no 
serious concern.20 Another work by Bisgaard proved 
that 28 days treatment with montelukast lead to disease 
improvement in infants between 3 to 36 months of age 
diagnosed with bronchiolitis.21 To our knowledge, till 
now one study has investigated the role of montelukast 
in URTI. A work by Kozer et al showed that 3 month 
treatment with 4 mg montelukast is not associated with 
reduction in URTI frequency and duration in preschool-
aged children.22 Compared to our study, they investigated 
different variables with a smaller sample size. However, 
they reported no benefits for preventive role of montelukast 
on URTI frequency and duration. Interestingly, Kozer’s 
study showed that montelukast use was associated with 
an increase in fever and in use of antibiotics. Like the 
mentioned work, we found no significant difference in 
the incidence of otitis in both study groups. Differences 
in number of family members, exposure to smoking, 
and lower socioeconomic profiles may partially explain 
the opposite findings. Leukotrienes can facilitate the 
migration of other inflammatory players by process 
which is known as chemotaxis.23 Montelukast blocks 
binding of leukotriene to its receptor and hence interrupts 
inflammatory responses. Montelukast is available in tablet 
and oral granules. It has rapid oral absorption. The half-life 
is about 3-6 hours and it is chiefly cleared by the liver.24 
In the present work, a 3-month montelukast therapy had 
no serious adverse effects. In general, montelukast is well 
tolerated by adults and children. Headache, abdominal 
pain, rash, and dyspepsia are seen in 2-10 % of patients.25 
Of note, FDA reported some concerns about central effects 
of montelukast; restlessness, hallucination, agitation, sleep 
disorders, and suicide. However, the frequency of these 
adverse effects are not defined.26  Till date, no serious 
interaction has been reported between monteluskat and 
other drugs using for management of childhood URTI.
The present study has a number of limitations. Our study 
was single center and our findings should be confirmed by 
multicenter trials. Of note, we did not assess the chronic 
effects of montelukast administration and we could not 
measure levels of leukoterienes in subjects with URTI. 
Our data was collected from parents’ records; therefore 
the level of compliance is not very clear and there has 
been no verification. Moreover, it is likely that our studied 
endpoints and drug effects have some errors. There is a 
sound rationale for further trials with greater statistical 
power among children of this age.
Conclusion
Our study indicates that 3 month treatment with 
montelukast is effective for reducing the incidence of URTI 
in young children. This treatment has an acceptable safety 
without any serious concern.
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